ANS
This article was originally published in The Gray Sheet
Executive Summary
Company submits final module of its PMA application for the totally implantable pulse generator (IPG) spinal cord stimulator for relief of chronic pain of the trunk and/or limbs. Advanced Neuromodulation Systems also continues to pursue its appeal regarding FDA's Feb. 23 denial of its reclassification petition for the IPG from a Class III to a Class II device. (1"The Gray Sheet" March 5, 2001, p. 10)
You may also be interested in...
CDRH Shocks ANS, Denies Downclassification of Spinal Cord Stimulator
FDA inspections of design controls under the Quality Systems Regulation do not provide enough assurance against device failure to allow the downclassification of the Class III totally implanted spinal cord stimulator (SCS) for pain relief, the agency maintains in a Feb. 23 letter to Advanced Neuromodulation Systems.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.